Pet Pharm Biotech Co., Ltd. (TPEX:7762)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
62.60
+0.80 (1.29%)
At close: Mar 6, 2026
Market Cap3.21B +9.0%
Revenue (ttm)159.02M +110.0%
Net Income19.25M
EPS0.41
Shares Out51.21M
PE Ratio152.73
Forward PEn/a
Dividend0.09 (0.14%)
Ex-Dividend DateAug 25, 2025
Volume38,008
Average Volume54,050
Open63.00
Previous Close61.80
Day's Range61.10 - 63.00
52-Week Range41.89 - 91.20
Betan/a
RSI33.14
Earnings DateApr 7, 2026

About Pet Pharm Biotech

Pet Pharm Biotech Co., Ltd. manufactures and sells pharmaceutical products. The company also engages in the research, development, and production of nuclear medicine drugs. Its products include FDG fluodeoxyglucose, naolixi, and sodium fluoride injections; and radioactive sodium iodide capsules. The company was founded in 2011 and is based in New Taipei City, Taiwan. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2011
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 7762
Full Company Profile

Financial Performance

In 2024, Pet Pharm Biotech's revenue was 130.70 million, an increase of 10.89% compared to the previous year's 117.87 million. Earnings were 14.51 million, an increase of 58.54%.

Financial Statements